WillItSurvive
Pharma and healthcare groups · Japan

Daiichi Sankyo

daiichisankyo.com ↗

Japanese pharma company behind Enhertu, a leading antibody-drug conjugate for cancer.

Defensible for now
Assessed 24 July 2026 · Evidence as of 24 July 2026
Real protection, with named pressure against it.
On the recordSince 24 July 2026 · Checkable from October 10, 2026 · Every call on the record Checkpoint: FDA PDUFA decision on ifinatamab deruxtecan
The call

Enhertu keeps growing fast and the chemistry lead holds, but a manufacturing miscalculation and rising Chinese ADC competitors are the first real cracks to watch.

Daiichi Sankyo makes Enhertu, a cancer drug that attaches medicine directly to tumor cells using a special chemistry process the company invented. It is hard to copy right now because the company owns the recipe, has approval in 90+ countries, and locked in deals with bigger drugmakers AstraZeneca and Merck to sell it. However, Pfizer (which bought the company Seagen) and Chinese competitors like Kelun-Botai and Hengrui are building similar drugs in the same space, and Daiichi Sankyo just admitted it overestimated factory capacity by roughly a billion dollars in 2025, which raises questions about whether the company can execute flawlessly. The biggest wildcard is whether Enhertu keeps growing fast enough to offset the company's reliance on just this one drug and the looming patent expiration around 2030 to 2035.

Why
01
AI pressure: AI-driven drug design labs (Insilico Medicine, Xaira Therapeutics). AI-assisted molecule design could speed rivals' ADC discovery, but has not replaced Daiichi Sankyo's DXd linker chemistry yet. Could AI do the core job? Unlikely.
02
Bigger players: Pfizer/Seagen and Roche ADC portfolios, plus Chinese entrants Kelun-Botai and Hengrui. Kelun-Botai's sacituzumab tirumotecan is FDA-approved and Hengrui's rezetecan is advancing, both competing directly in the same Trop-2/HER2 ADC space. Could a giant copy it? No, they are blocked.
03
What protects it. Proprietary DXd linker-payload chemistry, approvals in 90+ countries, and locked global distribution deals with AstraZeneca and Merck.
What would change this call
FDA PDUFA decision on ifinatamab deruxtecan due October 10, 2026. Approval would extend the DXd pipeline; a delay or rejection would weaken pipeline de-risking.
Company discloses resolved capacity/production plan within about 6 months of May 2026. Shows whether the $950M forecasting error was a one-off or reveals ongoing execution risk.
Kelun-Botai or Hengrui ADC sales/label expansions reported in US or EU markets within 12 months. Would show Chinese entrants converting approval into real revenue share against Daiichi Sankyo.
Key numbers
  • Enhertu FY2024 sales: JPY 552.8bn, +40% YoY (2025-03-31)
  • FY2025 revenue: JPY 2,123.0bn, +12.6% YoY (2026-03-31)
  • FY2026 guidance: JPY 2,280.0bn revenue, +7.4% (2026-05-11)
Named risks
  • Second manufacturing/demand forecasting error could recur after $950M FY2025 charge. Severity: high
  • Enhertu revenue concentration heading into mid-2030s patent cliff. Severity: medium
  • Unresolved freedom-to-operate uncertainty from ongoing Seagen/Pfizer ADC patent litigation. Severity: medium
  • Chinese ADC entrants Kelun-Botai and Hengrui gaining regulatory footing in overlapping targets. Severity: medium
Rivals, as read in July 2026
RivalDirectionEvidence
Pfizer/SeagencontestingWon Federal Circuit appeal Dec 2025 reversing $41.8M verdict, but related appeal dismissed June 2026 leaving IP overhang
Kelun-Botai/Merckgaining onFDA-approved Trop-2 ADC (sacituzumab tirumotecan) since Nov 2024 in overlapping target space
Hengruigaining onTrastuzumab rezetecan competes directly in HER2 ADC space as of 2026
AstraZenecacontestingKey Enhertu/Datroway co-commercialization partner but also develops its own ADC platform
Roche and AbbViecontestingLarge-cap oncology incumbents with overlapping HER2/ADC portfolios per 2026 industry landscape analysis
Questions people ask
Is Daiichi Sankyo profitable in FY2025?
Yes. For the fiscal year ended March 31, 2026, Daiichi Sankyo reported consolidated revenue of JPY 2,123.0 billion (+12.6% YoY) and core operating profit of JPY 360.0 billion (+15.1% YoY), despite absorbing a ~JPY 149.4 billion one-time manufacturing charge, per its May 11, 2026 results.
Why did Daiichi Sankyo take a $950 million loss?
Daiichi Sankyo overbuilt ADC manufacturing capacity relative to revised demand forecasts, resulting in a ~JPY 149.4 billion ($950M) extraordinary loss disclosed May 8, 2026, including JPY 75.7 billion in CMO compensation payments and an Odawara plant impairment charge.
Who is Daiichi Sankyo's biggest competitor in ADCs?
Pfizer/Seagen has been its longest-running rival via ADC patent litigation, though Daiichi won a Federal Circuit appeal reversing a $41.8M verdict in December 2025. Newer threats include FDA-approved Chinese ADC entrants Kelun-Botai and Hengrui in overlapping Trop-2/HER2 target space.
Could AI replace Daiichi Sankyo's drug development work?
No. AI is being used as an accelerant, not a replacement: Daiichi Sankyo signed AI partnerships with FRONTEO (Aug 2025), Lunit (Dec 2025), BostonGene (Feb 2026), and Tempus AI (March 2026) for toxicology and biomarker work, but its regulatory approvals and manufacturing moat remain unreplicable by AI.
Is Daiichi Sankyo hiring or cutting jobs?
Daiichi Sankyo is growing headcount. Company-reported group-wide employees were 19,765 as of March 31, 2025, up 1,039 (+5.55%) year over year, driven by global oncology commercial and R&D expansion, per its official sustainability data sheet.
Who owns Daiichi Sankyo?
Daiichi Sankyo is an independent public company with no parent, trading on the Tokyo Stock Exchange Prime Market under ticker 4568, with a market capitalization of approximately JPY 5.02 trillion as of June 2026.
Timeline
  • 2026-06-08Related Seagen v. Daiichi Sankyo patent appeal dismissed without a merits ruling
  • 2026-05-11Daiichi Sankyo unveils 5-year plan (FY2026-2030) targeting revenue over JPY 3.0 trillion
  • 2026-05-08FY2025 results show JPY 149.4 billion extraordinary loss from ADC manufacturing restructuring
  • 2026-04-24Shares fall more than 10% amid delayed FY2025 results announcement
  • 2026-03-25Tempus AI PRISM2 multimodal foundation-model collaboration announced
  • 2026-03FDA grants priority review for Enhertu in early breast cancer
  • 2026-02-17BostonGene AI-driven multimodal analytics collaboration announced
  • 2025-12-16Lunit AI biomarker and digital pathology collaboration signed
  • 2025-12-03Federal Circuit reverses $41.8M jury verdict, ruling favors Daiichi Sankyo over Seagen
  • 2025-08-18FRONTEO signs Phase 2 AI toxicology agreement with Daiichi Sankyo
Revision history
24 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
ZoetisBoston ScientificBecton Dickinson
More in Pharma and healthcare groups →
Sources